 In September 2015 the National Audit Office reported that no data had been collected on the 74,000 patients whose treatment had been funded, at a cost of nearly £1 billion, so it was impossible to discover whether the treatment had been effective.The Public Accounts Committee published a report on the fund in February 2016 which concluded that there was no evidence the fund was benefiting patients, extending lives or a good use of taxpayers' money.Prof Richard Sullivan, of King's College London and Dr Ajay Aggarwal of the London School of Hygiene & Tropical Medicine published a study in the Annals of Oncology in April 2017.